Research Article

Immobilization of Bone Morphogenetic Protein on DOPA- or Dopamine-Treated Titanium Surfaces to Enhance Osseointegration

Jeonghwa Kang, 1,2 Seiichi Tada, 1 Takashi Kitajima, 1 Tae Il Son, 1,3 Toshiro Aigaki, 1,2 and Yoshihiro Ito 1,2

1 Nano Medical Engineering Laboratory, RIKEN, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan
2 Department of Biological Science, Tokyo Metropolitan University, Minami-Osawa, Tokyo 192-0938, Japan
3 Department of Biotechnology and Bio-Environmental Technology (BET) Research Institute, Chung-Ang University, 40-1 San, Nae-Ri, Daeduck-myun, Ansung-si, Kyungki-do 456-756, Republic of Korea

Correspondence should be addressed to Yoshihiro Ito; y-ito@riken.jp

Received 15 October 2013; Revised 16 November 2013; Accepted 25 November 2013

Academic Editor: Oh Hyeong Kwon

Copyright © 2013 Jeonghwa Kang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Titanium was treated with 3,4-dihydroxy-L-phenylalanine (DOPA) or dopamine to immobilize bone morphogenetic protein-2 (BMP2), a biomolecule. DOPA and dopamine solutions turned into suspensions, and precipitates were produced at high pH. Both treatments produced a brown surface on titanium that was thicker at high pH than low pH. Dopamine produced a thicker layer than DOPA. The hydrophobicity of the surfaces increased after treatment with dopamine independent of pH. Furthermore, there were more amino groups in the layers formed at pH 8.5 than pH 4.5 in both treatments. Dopamine treatment produced more amino groups in the layer than DOPA. BMP2 was immobilized on the treated surfaces via a coupling reaction using carbodiimide. More BMP2 was immobilized on surfaces treated at pH 8.5 than pH 4.5 in both treatments. The immobilized BMP induced specific signal transduction and alkaliphosphatase, a differentiation marker. Thus, the present study demonstrates that titanium treated with DOPA or dopamine can become bioactive via the surface immobilization of BMP2, which induces specific signal transduction.

1. Introduction

Biomedical engineering has the potential to improve the quality of human life. Chemical modification of biological signaling molecules such as cell growth factors on implants is important in clinical therapeutics. Titanium is a biocompatible implant material but does not have specific biofunctionality. The adsorption of plasma proteins onto titanium surfaces plays an essential role in implant integration. The bioactivation of implants requires the functionalization of an implant surface with signaling molecules [1–3].

The formation of new bone is required for successful outcomes in bone fracture repair and dental implants. Efficient bone formation depends on the recruitment of osteoblast precursors to the site followed by osteoblast maturation, matrix deposition, and mineralization [4, 5]. Bone morphogenetic protein-2 (BMP2) is a signaling protein known to play important roles in the bone healing process and enhancing therapeutic efficacy [6, 7]. Therefore, coating or immobilizing BMP2 onto organic or inorganic surfaces is reported to enhance the osseointegration of materials [8–16].

Some researchers report physically coating titanium with BMP [17–19]. In addition, Kashiwagi et al. [20] prepared titanium-binding BMP using their selective titanium-binding peptide. On the other hand, in order to create stable covalent immobilization, Puleo et al. [21] performed plasma polymerization of allylamine on a titanium surface. Meanwhile, others prepared chitosan, dextran, or polymer layers on titanium to covalently immobilize BMP [22–25].

However, the covalent modification method of inorganic surfaces is limited, although there are some specific methodologies such as silane coupling. Therefore, Lee et al. [26, 27] devised a new convenient and universal method.
Underwater adhesive proteins containing 3,4-dihydroxy-l-phenylalanine (DOPA) from mussel protein play important roles in adhesion to various materials including polymers, metals, and ceramics. Therefore, Lee et al. hypothesized that the coexistence of catechol (i.e., DOPA) and amine (i.e., lysine) groups is crucial for achieving adhesion to a wide variety of materials. They consequently identified dopamine as a small-molecule compound that contains both functionalities and found that it is useful for the surface modification of various materials [26, 27]. Material surfaces were treated with dopamine to immobilize biological molecules including growth factors [28–34]. This dopamine treatment resulted in “polydopamine” or “melanin-like” films produced through the oxidation of dopamine or other catecholamines such as norepinephrine. Thus, this represents a very convenient and universal method for adding an organic layer to various materials including polymers, metals, and ceramics.

Meanwhile, Lai et al. [35] utilized this dopamine treatment method to conjugate BMP on titanium for the first time; the covalent conjugation was performed under alkaline conditions as suggested by Lee et al. [28]. The surface functionalization of TiO$_2$ nanotubes with BMP2 was beneficial for mesenchymal stem cell proliferation and differentiation. Their approach hints at potential applications in enhanced bone osseointegration stemming from the development of titanium-based implants.

We previously found that dopamine-treated surfaces contain amino groups that can be utilized for protein immobilization [33]. Therefore, in this study, we covalently immobilized BMP2 on dopamine-treated titanium surfaces using the amino groups. In addition to dopamine, DOPA was used for surface treatment as a link between titanium and BMP2, and the effect of BMP2 immobilization on titanium surfaces was investigated.

2. Materials and Methods

2.1. Materials. DOPA was purchased from Sigma (St. Louis, MO, USA). 3,4-Dihydroxyphenethylamine hydrochloride (dopamine) and N-hydroxysuccinimide (NHS) were purchased from Wako Pure Chemical Industries (Osaka, Japan). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (WSC) was obtained from Wako Pure Chemical Industries (Osaka, Japan) and 1M sodium bicarbonate (pH 9.0) was purchased from Dojindo (Kumamoto, Japan).

A glass plate (diameter, 15 mm; thickness, 1 mm) was coated by vacuum deposition with titanium (400 nm thick (±25%)) by Osaka Vacuum Industries Co. (Osaka, Japan) as previously reported [33]. Recombinant human BMP2 was purchased from R&D Systems Inc. (Minneapolis, MN, USA). Polyclonal anti-human BMP2 antibody was purchased from Abcam (Cambridge, UK). Horseradish peroxidase (HRP)-conjugated secondary antibody was obtained from Zymed (Carlsbad, CA, USA). Block Ace Powder was obtained from DS Pharma Biomedical (Sapporo, Japan).

2.2. Solution Measurement. Dopamine solution (2 mg/mL) was prepared in 10 mM Tris-buffer (adjusted to various pH values). After reacting at room temperature for 24 h, ultraviolet (UV) measurement was performed. Detection was carried out on the basis of using the absorbance at 500 nm. UV measurement was performed using a JASCO V-550 (Tokyo, Japan).

2.3. Surface Treatment. The surfaces of the plates were washed in hexane solution, cleaned with 6 M hydrogen chloride for 10 min, rinsed twice with triple-distilled water, dried in a vacuum oven for 24 h, and cleaned photochemically using an excimer UV lamp (USHIO Inc., Tokyo, Japan) for 10 min before incubation in dopamine solution; this method was applied to completely remove C–C bonds and avoid the subsequent decomposition of organic molecules. The complete removal of organic material was confirmed by the observed decrease in the water contact angle.

Next, DOPA or dopamine treatment was performed. The cleaned plates were placed in a flask containing 2 mg/mL dopamine or DOPA solution in water (pH 4.5) or 10 mM Tris-buffer (adjusted to pH 8.5). The reaction was performed at room temperature for 24 h. The treated TiO$_2$ was rinsed in fresh water and dried in a clean vacuum oven at room temperature for 24 h.

To immobilize BMP2 on the surfaces of the plates, BMP2 solution was mixed with an aqueous solution of 50 mM WSC and 20 mM NHS. The treated plates were immersed in the mixed solution for 48 h at 4°C. After incubation, the plates were washed 3 times with phosphate-buffered saline (PBS).

2.4. Surface Analysis. The static water contact angles of the sample surfaces were measured at 25°C in air by a contact-angle meter (Kyowa Interface Science Co., Tokyo, Japan) based on the sessile drop method. All contact angles were determined by averaging 10 different point values measured on each dopamine-treated surface.

The thickness of the polymer was measured by an ellipsometer M-2000DI (JA Woollam Company, NE, USA) from 195 to 1,500 nm at 3 angles: 65°, 70°, and 75°. The surface roughness was analyzed by a NewView 5032 apparatus (Zygo Co., Middlefield, CT, USA).

Fluorescein isothiocyanate (FITC) was used to determine the amount of amino groups on a surface. FITC solution (100 μL, 10 mg/mL) in dimethylsulfoxide was mixed with 1 mL 0.1 M sodium bicarbonate solution (pH 9.0). The sample plate modified with DOPA or dopamine was incubated in the solution at room temperature for 1 h and subsequently rinsed 10 times with PBS. FITC was quantified by an AxioVision instrument (Zeiss, Oberkochen, Germany) with a Cool SNAP HQ camera (Photometrics, Tokyo, Japan).

Immobilized BMP2 was detected using an anti-BMP2 antibody. The plate was rinsed with PBS-Tween (PBS-T) (0.1%) and blocked by incubation in an aqueous solution of 1% nonfat milk for 30 min. The plate was subsequently incubated with an anti-BMP2 antibody (1:2,000 dilution) overnight at 4°C and washed 3 times with PBS-T (0.1%) before being incubated with an HRP-conjugated secondary antibody (1:10,000 dilution) for 1 h at room temperature. After washing 3 times with PBS-T (0.1%), a chemiluminescence
reaction was performed using an ECL Plus Western Blotting Detection System (GE Healthcare, Fairfield, CT, USA) and was observed by Light-Capture (ATTO, Tokyo, Japan).

2.5. Cell Culture. BRE-Luc C2C12 cells, which have a luciferase reporter gene with a BMP2-specific enhancer derived from inhibitor of differentiation (Id)1 promoter, were cultured in DMEM (Sigma, St. Louis, MO, USA) supplemented with 5% fetal bovine serum (Moregate Inc., Hamilton, Waikato, New Zealand) and 1% penicillin-streptomycin (Wako Pure Chemical Industries, Osaka, Japan) at 37°C in 95% humidified air/5% CO₂. The cells were then washed with 5 mL PBS and harvested using a 0.25% trypsin solution containing 1 mM EDTA (Wako Pure Chemical Industries, Osaka, Japan) for 3 min at 37°C. Finally, the recovered cells were suspended in medium for the subsequent in vitro examination.

To monitor BMP signaling, the cell suspension was added to 24-well tissue culture polystyrene plates (0.5 mL/well, 1 × 10⁵ cells/mL) containing the samples, which were previously washed with sterilized PBS. After the cells were cultured in a 5% CO₂ atmosphere at 37°C for 48 h, they were washed with PBS and disrupted with lysis reagent (Promega, Madison, WI, USA). The luciferase activity in the lysate was measured using a luciferase assay reagent kit (Promega, Madison, WI, USA) with a Mithras LB940 luminescence plate reader (Berthold Technologies, Bad Wildbad, Germany). The observed activity was normalized to the protein content in the cell lysate, which was determined using a BCA protein assay kit (Pierce, Rockford, IL, USA).

As a marker of osteogenic differentiation, alkaline phosphatase activity was measured as previously reported [36]. C2C12 cells suspension was added to 24-well tissue culture polystyrene plates (0.5 mL/well, 5 × 10³ cells/mL) containing the samples, which were previously washed with sterilized PBS. The cells were cultured in a 5% CO₂ atmosphere at 37°C for 10 days (changing the media every 2 days), washed with Tris-buffered saline, and disrupted with Tris-buffered saline containing 0.2% Triton X-100. The alkaline phosphatase activity was measured using the fluorescent substrate, 4-methylumbelliferyl phosphate (Sigma, St. Louis, MO, USA), with a Mithras LB940 luminescence plate reader. The observed activity was normalized to the protein content in the cell lysate, which was determined using a BCA protein assay kit.

2.6. Statistical Analysis. Statistical analyses were performed using Student’s t-test for paired samples and analysis of variance for multiple samples.

3. Results and Discussion

3.1. DOPA and Dopamine Treatment. The properties of DOPA and dopamine solution were investigated on the basis of turbidity (Figure 1). Both solutions were transparent at low pH even after 24 h and turned turbid and brown at high pH. After 24 h, some precipitate was found in dopamine solution at high pH. Although the turbidity change of the DOPA solution appeared to be greater than that of dopamine, the lower turbidity was due to the precipitation of aggregated dopamine. Therefore, dopamine was considered more reactive than on DOPA.

When titanium-coated glass was treated with either DOPA or dopamine, the surface turned brown at pH 8.5 (Figure 2). The brown color was denser on dopamine-treated surfaces than DOPA-treated surfaces. In contrast, no significant color change was observed when the surfaces were treated at pH 4.5. The color change coincided with the thickness. The layer formed by DOPA was thinner than that formed by dopamine (Table 1). In the case of dopamine, the formed layer at pH 8.5 was about 28 times thicker than that formed at pH 4.5 (Table 1); in the case of DOPA, the surface was less than 5 times thicker.

However, the assessment of surface hydrophilicity on the basis of contact angle measurements revealed that the water contact angle of surfaces increased with DOPA or dopamine treatment even at pH 4.5; the contact angles on the surface were almost the same with treatment at pH 4.5 and pH 8.5 (Table 1). This indicates that the titanium surfaces were fully covered by DOPA or dopamine at pH 4.5 as described previously [33]. Therefore, the present results indicate the effect of dopamine is stronger than that of DOPA. The carboxyl group in DOPA is specifically considered to reduce the reactivity.
Table 1: Water contact angle and thickness of the DOPA and dopamine layers formed on titanium.

| Treatment | pH   | Water contact angle (°)   | Thickness (nm)   |
|-----------|------|---------------------------|------------------|
| —         | —    | 0                         | 0                |
| DOPA      | 4.5  | 64.0 ± 1.9                | 0.676 ± 0.017    |
|           | 8.5  | 67.8 ± 1.4                | 3.225 ± 0.073    |
| Dopamine  | 4.5  | 51.4 ± 1.9                | 0.798 ± 0.073    |
|           | 8.5  | 54.7 ± 1.1                | 22.05 ± 1.048    |

3.2. Biological Activity. After confirming the immobilization of BMP2 on titanium surfaces, BRE-Luc C2C12 cells were seeded and incubated for 2 days. Id proteins act as dominant-negative inhibitors of basic helix-loop-helix transcription factors. Id and basic helix-loop-helix proteins dictate cellular programs of differentiation and proliferation in various cell types in an opposing manner. BMP2 inhibits myogenic differentiation and regulates bone formation. Id1 is strongly induced by BMP2 and is an important mediator of the inhibitory effect of BMP2 on myogenic differentiation [36, 37]. The results of luciferase activity indicate that BMP2 immobilized on titanium surfaces significantly activated the reporter gene (Figure 6). Thus, the results demonstrate that BMP2 interacts with the receptor even after immobilization. The induction on dopamine-treated and BMP2-immobilized surfaces was more enhanced than on DOPA-treated and BMP-immobilized surfaces, although the difference was not significant.

An alkali phosphatase assay was performed on C2C12 cells cultured for 10 days on the titanium surface with immobilized BMP2 (Figure 7). These cells are usually employed to study the differentiation of myoblasts and osteoblasts. Alkaline phosphatase is a marker of bone formation; its induction indicates cell differentiation from the myoblastic to the osteoblastic lineage. Although no significant difference of cultured cells was observed by microscopy, the immobilized
BMP2-induced osteogenic differentiation. There was no significant difference between BMP2-immobilized surfaces.

Covalent immobilization using functional groups in BMP is categorized into amino groups and carboxyl groups. Tsujigiwa et al. [9], Park et al. [11], Schmoekel et al. [12], and Lai et al. [35] used amino groups in BMP. On the other hand, Puleo et al. [21] used carboxyl groups in BMP. In this study, we employed carboxyl groups in BMP for covalent immobilization and found a significant effect of immobilized BMP.

4. Conclusions

BMP2 is covalently immobilized on dopamine-treated titanium surfaces. The immobilized BMP2 specifically interacts with myoblasts and induces osteogenic differentiation. Therefore, the present method is convenient for covalently immobilizing BMP2 while retaining its biological activity.

Acknowledgments

BRE-Luc C2C12 cells were kindly provided by Dr. Kiyotaka Shiba of the Cancer Institute of the JFCR. This work was supported by JSPS KAKENHI (Grant no. 22220009).

References

[1] M. Bongio, J. J. P. van der Beuken, S. C. G. Leeuwenburgh, and J. A. Jansen, “Development of bone substitute materials: from “biocompatible” to ‘instructive’,” Journal of Materials Chemistry, vol. 20, no. 40, pp. 8747–8759, 2010.
[2] B. Joddar and Y. Ito, “Biological modifications of materials surfaces with proteins for regenerative medicine,” Journal of Materials Chemistry, vol. 21, no. 36, pp. 13737–13755, 2011.
[3] D. Zhou and Y. Ito, “Inorganic material surfaces made bioactive by immobilizing growth factors for hard tissue engineering,” RSC Advances, vol. 3, no. 28, pp. 11095–11106, 2013.
[4] N. Jaiswal, S. E. Haynesworth, A. I. Caplan, and S. P. Bruder, “Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro,” Journal of Cellular Biochemistry, vol. 64, no. 2, pp. 295–312, 1997.
[5] L. X. Bi, D. J. Simmons, and E. Mainous, “Expression of BMP-2 by rat bone marrow stromal cells in culture,” Calcified Tissue International, vol. 64, no. 1, pp. 63–68, 1999.
[6] N. Nishii, M. Arai, N. Yanai, A. Togari, and T. Nakabayashi, “Effect of bone morphogenetic protein-2 (BMP-2) or troglitazone, as an inducer of osteogenic cells or adipocytes, on differentiation of a bone marrow mesenchymal progenitor cell line established from temperature-sensitive (ts) simian virus (SV) 40 T-antigen gene transgenic mice,” Biological and Pharmaceutical Bulletin, vol. 32, no. 1, pp. 10–17, 2009.
[7] W. K. Hsu, O. Sugiyama, S. H. Park et al., “Lentiviral-mediated BMP-2 gene transfer enhances healing of segmental femoral defects in rats,” Bone, vol. 40, no. 4, pp. 931–938, 2007.
[8] V. Karageorgiou, L. Meinel, S. Hofmann, A. Malhotra, V. Voloch, and D. Kaplan, “Bone morphogenetic protein-2 decorated silk fibroin films induce osteogenic differentiation of human bone marrow stromal cells,” Journal of Biomedical Materials Research A, vol. 71, no. 3, pp. 528–537, 2004.
[9] H. Tsujigiwa, H. Nagatsuka, M. Gunduz et al., “Effects of immobilized recombinant human bone morphogenetic protein-2/succinylated type I atelocollagen on cellular activity of ST2
cells,” *Journal of Biomedical Materials Research A*, vol. 75, no. 1, pp. 210–215, 2005.

[10] B. Han, N. Perelman, B. Tang, F. Hall, E. C. Shors, and M. E. Nimni, “Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with type I collagen enhance osteogenesis in a rat cranial defect model,” *Journal of Orthopaedic Research*, vol. 20, no. 4, pp. 747–755, 2002.

[11] Y. J. Park, K. H. Kim, J. Y. Lee et al., “Immobilization of bone morphogenetic protein-2 on a nanofibrous chitosan membrane for enhanced guided bone regeneration,” *Biotechnology and Applied Biochemistry*, vol. 43, no. 1, pp. 17–24, 2006.

[12] H. G. Schmoekel, F. E. Weber, J. C. Schense, K. W. Grätz, P. Schwalder, and J. A. Hubbell, “Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices,” *Biotechnology and Bioengineering*, vol. 89, no. 3, pp. 253–262, 2005.

[13] U. Edlund, S. Dänmark, and A. Albertsson, “A strategy for the covalent functionalization of resorbable polymers with heparin and osteoinductive growth factor,” *Biomacromolecules*, vol. 9, no. 3, pp. 901–905, 2008.

[14] H. Shen, X. Hu, F. Yang, J. Bei, and S. Wang, “The bioactivity of rhBMP-2 immobilized poly(lactide-co-glycolide) scaffolds,” *Biomaterials*, vol. 30, no. 18, pp. 3150–3157, 2009.

[15] A. Schussele, H. Mayr, J. Tessmar, and A. Goeppferich, “Enhanced bone morphogenetic protein-2 performance on hydroxyapatite ceramic surfaces,” *Journal of Biomedical Materials Research A*, vol. 90, no. 4, pp. 959–971, 2009.

[16] F. R. Kloss, R. Gassner, J. Preiner et al., “The role of oxygen termination of nanocrystalline diamond on immobilisation of BMP-2 and subsequent bone formation,” *Biomaterials*, vol. 29, no. 16, pp. 2433–2442, 2008.

[17] M. Wiemann, H. P. Jennissen, H. Rumpf et al., “A reporter-cell assay for the detection of BMP-2 immobilized on porous and nonporous materials,” *Journal of Biomedical Materials Research*, vol. 62, no. 1, pp. 119–127, 2002.

[18] H. Schlepheke, A. Aref, D. Scharnweber, S. Bierbaum, S. Roessler, and A. Sewing, “Effect of immobilized bone morphogenetic protein 2 coating of titanium implants on peri-implant bone formation,” *Clinical Oral Implants Research*, vol. 16, no. 5, pp. 563–569, 2005.

[19] J. Hall, R. G. Soransen, J. M. Wozney, and U. M. E. Wikesjo, “Bone formation at rhBMP-2-coated titanium implants in the rat ectopic model,” *Journal of Clinical Periodontology*, vol. 34, no. 5, pp. 444–451, 2007.

[20] K. Kashiwagi, T. Tsuji, and K. Shiba, “Directional BMP-2 for functionalization of titanium surfaces,” *Biomaterials*, vol. 30, no. 6, pp. 1166–1175, 2009.

[21] D. A. Puleo, R. A. Kissling, and M.-S. Sheu, “A technique to immobilize bioactive proteins, including bone morphogenetic protein-4 (BMP-4), on titanium alloy,” *Biomaterials*, vol. 23, no. 9, pp. 2079–2087, 2002.

[22] T. Y. Lim, W. Wang, Z. Shi, C. K. Poh, and K. G. Neoh, “Human bone marrow-derived mesenchymal stem cells and osteoblast differentiation on titanium with surface-grafted chitosan and immobilized bone morphogenetic protein-2,” *Journal of Materials Science*, vol. 20, no. 1, pp. 1–10, 2009.

[23] Z. L. Shi, K. G. Neoh, E. T. Kang, K. P. Chye, and W. Wang, “Surface functionalization of titanium with carboxymethyl chitosan and immobilized bone morphogenetic protein-2 for enhanced osseointegration,” *Biomacromolecules*, vol. 10, no. 6, pp. 1603–1611, 2009.

[24] Z. Shi, K. G. Neoh, E. Kang, C. Poh, and W. Wang, “Titanium with surface-grafted dextran and immobilized bone morphogenetic protein-2 for inhibition of bacterial adhesion and enhancement of osteoblast functions,” *Tissue Engineering A*, vol. 15, no. 2, pp. 417–426, 2009.

[25] C. Lorenz, A. Hoffmann, G. Gross et al., “Coating of titanium implant materials with thin polymeric films for binding the signaling protein BMP2,” *Macromolecular Bioscience*, vol. 11, no. 2, pp. 234–244, 2011.

[26] H. Lee, S. M. Dellatore, W. M. Miller, and P. B. Messersmith, “Mussel-inspired surface chemistry for multifunctional coatings,” *Science*, vol. 318, no. 5849, pp. 426–430, 2007.

[27] C. E. Brubaker and P. B. Messersmith, “The present and future of biologically inspired adhesive interfaces and materials,” *Langmuir*, vol. 28, no. 4, pp. 2200–2205, 2012.

[28] H. Lee, J. Rho, and P. B. Messersmith, “Facile conjugation of biomolecule onto surfaces via mussel adhesive protein inspired coatings,” *Advanced Materials*, vol. 21, no. 4, pp. 431–434, 2009.

[29] C. K. Poh, Z. Shi, T. Y. Lim, K. G. Neoh, and W. Wang, “The effect of VEGF functionalization of titanium on endothelial cells in vitro,” *Biomaterials*, vol. 31, no. 7, pp. 1578–1585, 2010.

[30] Y. B. Lee, Y. M. Shin, J. H. Lee et al., “Polydopamine-mediated immobilization of multiple bioactive molecules for the development of functional vascular graft materials,” *Biomaterials*, vol. 33, no. 33, pp. 8343–8352, 2012.

[31] K. K. Yang, J. S. Lee, J. J. Kim et al., “Polydopamine-mediated surface modification of scaffold materials for human neural stem cell engineering,” *Biomaterials*, vol. 33, no. 29, pp. 6952–6964, 2012.

[32] Y. M. Shin, Y. B. Lee, S. J. Kim et al., “Mussel-inspired immobilization of vascular endothelial growth factor (VEGF) for enhanced endothelialization of vascular grafts,” *Biomacromolecules*, vol. 13, no. 7, pp. 2020–2028, 2012.

[33] J. Kang, M. Sakuragi, A. Shibata et al., “Immobilization of epidermal growth factor on titanium and stainless steel surfaces via dopamine treatment,” *Materials Science and Engineering C*, vol. 32, no. 8, pp. 2552–2561, 2012.

[34] B. Joddar, A. Albayrak, J. Kang, M. Nishihara, H. Abe, and Y. Ito, “Sustained delivery of siRNA from dopamine-coated stainless steel surfaces,” *Acta Biomaterialia*, vol. 9, no. 5, pp. 6753–6761, 2013.

[35] M. Lai, K. Cai, L. Zhao, X. Chen, Y. Hou, and Z. Yang, “Surface functionalization of TiO2 nanotubes with bone morphogenetic protein 2 and its synergistic effect on the differentiation of mesenchymal stem cells,” *Biomacromolecules*, vol. 12, no. 4, pp. 1097–1105, 2011.

[36] T. Mazaki, T. Kitajima, Y. Shiozaki et al., “Id1 genetic protein-specific response element in the Id1 promoter,” *Journal of Functional Foods*, vol. 10, pp. 1097–1105, 2013.

[37] O. Korchnyskyi and P. Ten Dijke, “Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Idl promotor,” *Journal of Biological Chemistry*, vol. 277, no. 7, pp. 4883–4891, 2002.